Sinopep

Sinopep Biopharma is a China-based contract development and manufacturing organization (CDMO) specializing in peptides, oligonucleotides, and small molecules. According to its official website, the company positions itself as a full-service Peptide and Oligo CDMO offering end-to-end CMC development and commercial manufacturing solutions for global partners. Its services span discovery research through commercial-scale GMP production, covering custom peptide synthesis, custom oligo synthesis (ASO, siRNA, miRNA, PMO, aptamer, CpG, decoy), conjugate synthesis, and FTE-based research services. On the CDMO side, Sinopep provides GMP manufacturing for peptide and oligonucleotide new chemical entities (NCEs), including CMC development, scale-up, and commercial GMP supply. The company states that its flexible, modular systems enable seamless scale-up from milligrams to hundreds of kilograms, supporting projects from early discovery through full commercial production. It also offers generic APIs in peptides, oligonucleotides, and small molecules, as well as finished dosage form (FDF) formulation services. Sinopep describes itself as committed to advancing the frontiers of peptides, oligonucleotides, and small molecules as transformative therapeutic solutions, aiming to set new standards across the industry through innovation, operational excellence, and scalable manufacturing. The company serves global pharmaceutical partners and maintains a media relations function for business and subject-matter inquiries.

Sinopep Biopharma has developed as a China-based CDMO focused on peptide and oligonucleotide manufacturing. Public information on the company's official website describes its evolution around integrated CMC development and commercial GMP supply capabilities. The company presents itself as a full-service Peptide and Oligo CDMO, with services that have expanded from discovery-phase custom synthesis to late-phase and commercial production of peptide, oligonucleotide, and small molecule NCEs. According to its website, Sinopep's service portfolio grew to include discovery services such as custom peptide synthesis, peptide modifications, custom oligo synthesis for modalities including ASO, siRNA, miRNA, PMO, aptamer, CpG, and decoy, as well as conjugate synthesis for peptide, small-molecule, and oligo conjugates (e.g., POCs, PPMOs). The company also offers an FTE (Full-Time Equivalent) model for research services. On the CDMO side, Sinopep expanded into GMP manufacturing for peptides and oligonucleotide NCEs, generic APIs, and finished dosage form (FDF) formulation services. The company emphasizes flexible, modular manufacturing systems that enable scale-up from milligrams to hundreds of kilograms, supporting clients from early discovery through full commercial production. Its website highlights integrated CDMO services built for commercial readiness, including development, scale-up, and commercial GMP supply in one integrated program. Sinopep states that it is committed to advancing peptides, oligonucleotides, and small molecules as transformative therapeutic solutions, and positions itself at the forefront of the global pharmaceutical landscape by delivering life-saving solutions and driving progress for partners worldwide. The company maintains a news and media relations function, publishing brochures, citations, insights, past events, press releases, publications, sustainability content, videos, and whitepapers, including a whitepaper on Quality by Design for an Oral Semaglutide Tablet.

• Sinopep publishes a whitepaper on Quality by Design for an Oral Semaglutide Tablet, listed under Formulation and Whitepaper categories on its news page.

• Sinopep exhibits at the Boulder Peptide Symposium, listed under Past Events on its news page.

A CDMO focused on the peptide field, providing one-stop solutions

Product categories. peptide APIs · small molecule APIs · CDMO services

• 2025

  Heavily Fined by the CSRC for Inflated Revenue and Profit and False Content in Offering Documents

  In December 2025, Sinopep received a final penalty decision involving the inflation of revenue by RMB 30 million and profit by approximately RMB 25.95 million in 2021, as well as the fabrication of major false content in public offering documents. The company and the responsible individuals were penalized. This entry reflects the final decision, as distinguished from the earlier advance notice.

  Source

Read more

1. 1GMP Peptide CDMO & Oligo Manufacturing - Sinopep Biopharmasinopep.com
2. 2About Us - Sinopep Biopharmasinopep.com
3. 3CDMO Services - Sinopep Biopharmasinopep.com
4. 4News - Sinopep Biopharmasinopep.com
5. 5Heavily Fined by the CSRC for Inflated Revenue and Profit and False Content in Offering Documentspaper.cnstock.com
6. 6Heavily Fined by the CSRC for Inflated Revenue and Profit and False Content in Offering Documentsjiemian.com